Latest | F'cast | |
---|---|---|
Div Yield | 0.0% | 0.0% |
Div Cover | n/a | n/a |
Op Mrgn | -201.4% | n/a |
ROCE | n/a |
Latest | F'cast | |
---|---|---|
P/E | n/a | n/a |
PEG | n/a | n/a |
Pr/Revenue | 6.9 | n/a |
Pr/Book | 4.3 |
Latest | F'cast | |
---|---|---|
Revenue | -60.8% | n/a |
PBT | n/a | n/a |
EPS | n/a | n/a |
DPS | n/a | n/a |
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
31-Mar-20 | 3.90 | (1.07) | (3.20)p | n/a | n/a | n/a | n/a | 0.0% |
31-Mar-21 | 4.16 | (1.26) | (0.12)p | n/a | n/a | n/a | n/a | 0.0% |
31-Mar-22 | 4.80 | (1.33) | (4.60)p | n/a | n/a | n/a | n/a | 0.0% |
31-Mar-23 | 2.90 | (2.86) | (10.00)p | n/a | n/a | n/a | n/a | 0.0% |
31-Mar-24 | 1.14 | (2.29) | (3.90)p | n/a | n/a | n/a | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
Update on U.S. Patent for OptiMAL® | 22-May-2025 | 14:33 | RNS |
Issue of shares to non-executive directors | 07-May-2025 | 07:00 | RNS |
Director/PDMR Shareholding | 06-May-2025 | 10:53 | RNS |
Traded | Action | Notifier | Price | Amount | Value |
---|---|---|---|---|---|
06-May-25 | Buy | Matthew Baker | 6.10p | 55,327 | £3,374.95 |
06-May-25 | Buy | Colin Walsh | 6.10p | 221,331 | £13,501.19 |
06-May-25 | Buy | Simon Gordon Douglas | 6.10p | 61,475 | £3,749.98 |
Currency | UK Pounds |
Share Price | 6.73p |
Change Today | -0.12p |
% Change | -1.70 % |
52 Week High | 10.20 |
52 Week Low | 2.90 |
Volume | 226,273 |
Shares Issued | 113.66m |
Market Cap | £7.65m |
Beta | 0.03 |
RiskGrade | 464 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
No dividends found |
Time | Volume / Share Price |
16:19 | 3 @ 6.90p |
11:29 | 712 @ 7.09p |
10:36 | 20,000 @ 6.55p |
10:28 | 29,630 @ 6.54p |
09:50 | 10,448 @ 7.14p |
Chair | Simon Gordon Douglas |
CEO | Adrian Kinkaid |
You are here: research